Ligand Pharma (LGND) Misses Q4 EPS by 45c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Ligand Pharma (LGND) Misses Q4 EPS by 45c

Ligand Reports Fourth Quarter and Full Year 2016 Financial Results

February 23, 2017 4:01 PM EST

Conference Call Begins at 4:30 p.m. Eastern Time Today

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time.

2016 was an exceptional year for Ligand. We reported substantial revenue growing more than 50% over last year and strong operating cash flow. Evomela, a new commercial product with a high royalty rate to Ligand, launched and joined... More